Primary Central Nervous System Lymphoma

Seminars in Radiation Oncology

Volumn 17, Issue 3, 2007, Pages 223-229

  Mohile, Nimish A ^a   Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE; GADOLINIUM; IDARUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; THIOTEPA; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC PROCEDURE; HUMAN; INCIDENCE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

ADRENAL CORTEX HORMONES; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; LYMPHOMA, NON-HODGKIN; METHOTREXATE; REMISSION INDUCTION; SURVIVAL RATE;

EID: 34250782790     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.02.008     Document Type: Article

References (62)

1. DeAngelis L.M., Gutin P.H., and Leibel S.A. Intracranial Tumors. Diagnosis and Treatment. (ed 1) (2002), Martin Dunitz, London, UK
2. Omuro A.M., Ben-Porat L.S., and Panageas K.S. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62 (2005) 1595-1600
3. Schabet M.M. Epidemiology of primary CNS lymphoma. J Neurooncol 43 (1999) 199-201
4. Coté T.R., Manns A., Hardy C.R., and AIDS/Cancer Study Group. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J Natl Cancer Inst 88 (1996) 675-679
5. Olson J.E., Janney C.A., and Rao R.D. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and end results analysis. Cancer 95 (2002) 1504-1510
6. Corn B.W., Marcus S.M., and Topham A. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?. Cancer 79 (1997) 2409-2413
7. Eby N.L., Grufferman S., and Flannelly C.M. Increasing incidence of primary brain lymphoma in the US. Cancer 62 (1988) 2461-2465
8. Hao D., DiFrancesco L.M., and Brasher P.M. Is primary CNS lymphoma really becoming more common?. A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996. Ann Oncol 10 (1999) 65-70
9. Kadan-Lottick N.S., Skluzacek M.C., and Gurney J.G. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95 (2002) 193-202
10. Ferreri A.J., Abrey L.E., and Blay J.Y. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21 (2003) 2407-2414
11. Shenkier T.N., Blay J.Y., and O'Neill B.P. Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 23 (2005) 2233-2239
12. Küker W., Nägele T., and Korfel A. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72 (2005) 169-177
13. Pollack I.F., Lunsford L.D., and Flickinger J.C. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63 (1989) 939-947
14. Corry J., Smith J.G., and Wirth A. Primary central nervous system lymphoma: Age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41 (1998) 615-620
15. Blay J.Y., Lasset C., and Carrie C. Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. Br J Cancer 67 (1993) 1136-1141
16. Ferreri A.J., Blay J.Y., and Reni M. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 (2003) 266-272
17. Abrey L.E., Ben-Porat L., and Panageas K.S. Primary central nervous system lymphoma: The Memorial Sloan Kettering Cancer Center prognostic model. J Clin Oncol 24 (2006) 5711-5715
18. Mohile N.A., DeAngelis L.M., and Abrey L.E. The role of cranial and body 18 flouro-deoxyglucose positron emissiton tomography in primary CNS lymphoma. Proc Am Soc Clin Oncol 24 (2006) 66s
19. Todd F.D., Miller C.A., and Yates A.J. Steroid-induced remission in primary malignant lymphoma of the central nervous system. Surg Neurol 26 (1986) 79-84
20. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 43 (1999) 237-239
21. Lai R., Rosenblum M.K., and DeAngelis L.M. Primary CNS lymphoma: A whole-brain disease?. Neurology 59 (2002) 1557-1562
22. Shibamoto Y., Hayabuchi N., and Hiratsuka J. Is whole-brain irradiation necessary for primary central nervous system lymphoma?. Patterns of recurrence after partial-brain irradiation. Cancer 97 (2003) 128-133
23. Blay J.Y., Conroy T., and Chevreau C. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16 (1998) 864-871
24. Nelson D.F., Martz K.L., and Bonner H. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival?. Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23 (1992) 9-17
25. Bessell E.M., López-Guillermo A., and Villá S. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20 (2002) 231-236
26. Abrey L.E., Yahalom J., and DeAngelis L.M. Treatment for primary CNS lymphoma: The next step. J Clin Oncol 18 (2000) 3144-3150
27. Gavrilovic I.T., Hormigo A., and Yahalom J. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24 (2006) 4570-4574
28. Yahalom J., Shah G.D., Lai R.K., et al. Reduced-dose whole brain radiotherapy (WBRT) following complete response to immuno-chemotherapy in patients with primary CNS lymphoma (PCNSL). Int J Rad Onc Biol Phys 66 (2006) s84 (abstr)
29. Lachance D.H., Brizel D.M., and Gockerman J.P. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44 (1994) 1721-1727
30. Schultz C., Scott C., and Sherman W. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14 (1996) 556-564
31. Shibamoto Y., Tsutsui K., and Dodo Y. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 65 (1990) 1907-1912
32. Brada M., Dearnaley D., and Horwich A. Management of primary cerebral lymphoma with initial chemotherapy: Preliminary results and comparison with patients treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 18 (1990) 787-792
33. Skarin A.T., Zuckerman K.S., and Pitman S.W. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 50 (1977) 1039-1047
34. Ferreri A.J., Guerra E., and Regazzi M. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90 (2004) 353-358
35. DeAngelis L.M., Yahalom J., and Thaler H.T. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10 (1992) 635-643
36. Cheng A.L., Yeh K.H., and Uen W.C. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: A pilot study of the BOMES protocol. Cancer 82 (1998) 1946-1951
37. Batchelor T., Carson K., and O'Neill A. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21 (2003) 1044-1049
38. DeAngelis L.M., Seiferheld W., and Schold S.C. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20 (2002) 4643-4648
39. Ferreri A.J., Dell'Oro S., and Foppoli M. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 66 (2006) 1435-1438
40. Omuro A.M., DeAngelis L.M., and Yahalom J. Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up. Neurology 64 (2005) 69-74
41. Poortmans P.M., Kluin-Nelemans H.C., and Haaxma-Reiche H. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 (2003) 4483-4488
42. Bessell E.M., Graus F., and Lopez-Guillermo A. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: Long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59 (2004) 501-508
43. Slevin M.L., Piall E.M., and Aherne G.W. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1 (1983) 546-551
44. Hiraga S., Arita N., and Ohnishi T. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91 (1999) 221-230
45. Khan R.B., Shi W., and Thaler H.T. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol 58 (2002) 175-178
46. Shapiro W.R., Young D.F., and Mehta B.M. Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. New Engl J Med 293 (1975) 161-166
47. Panageas K.S., Elkin E.B., and DeAngelis L.M. Trends in survival from primary central nervous system lymphoma, 1975-1999: A population-based analysis. Cancer 104 (2005) 2466-2472
48. Milpied N., Deconinck E., and Gaillard F. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350 (2004) 1287-1295
49. Abrey L.E., Moskowitz C.H., and Mason W.P. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis. J Clin Oncol 21 (2003) 4151-4156
50. Cheng T., Forsyth P., and Chaudhry A. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31 (2003) 679-685
51. Illerhaus G., Marks R., and Ihorst G. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24 (2006) 3865-3870
52. Neuwelt E.A., Goldman D.L., and Dahlborg S.A. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9 (1991) 1580-1590
53. Guha-Thakurta N., Damek D., and Pollack C. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients. J Neurooncol 43 (1999) 259-268
54. Arellano-Rodrigo E., López-Guillermo A., and Bessell E.M. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70 (2003) 219-224
55. Herrlinger U., Brugger W., and Bamberg M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54 (2000) 1707-1708
56. Pels H., Schulz H., and Schlegel U. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: Experience with two cases and review of the literature. Onkologie 26 (2003) 351-354
57. Reni M., Mason W., and Zaja F. Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Cancer 40 (2004) 1682-1688
58. Soussain C., Suzan F., and Hoang-Xuan K. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19 (2001) 742-749
59. Enting R.H., Demopoulos A., and DeAngelis L.M. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63 (2004) 901-903
60. Correa D.D., DeAngelis L.M., and Shi W. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62 (2004) 548-555
61. Lai R., Abrey L.E., and Rosenblum M.K. Treatment-induced leukoencephalopathy in primary CNS lymphoma: A clinical and autopsy study. Neurology 62 (2004) 451-456
62. Thiessen B., and DeAngelis L.M. Hydrocephalus in radiation leukoencephalopathy: Results of ventriculoperitoneal shunting. Arch Neurol 55 (1998) 705-710